IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine - IVI

News and stories
Careers
Events
Contact us
Donate
한국어

Who We Are
What We Do
- Overview
- Discover
- Develop
- Deliver
- Build Capacity
- Disease Areas
  - Cholera
  - Typhoid
  - Dengue
  - MERS
  - Schistosomiasis
  - Chikungunya
  - COVID-19
  - AMR
    - RADAAR
  - Other
Where We Work
- Overview Map
- IVI Member States
Our Impact

✕

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

Home
News IVI in the Media
IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

https://www.outsourcing-pharma.com/Article/2019/04/23/IVI-receives-15.7m-to-conduct-Ph-III-trials-of-typhoid-vaccine?

Outsourcing-pharma.com, 2019/04/23

Related posts

05/16/2022

Chosun Ilbo | Jerome Kim, Director General of International Vaccine Institute, named a distinguished professor at Seoul National University

News and stories
Press Releases
Announcements
IVI in the Media
Blog
Newsletters

Subscribe to usemail addressSubscribe

Social Media

Stay Connected

Vision & Mission
Why Vaccines
IVI in Brief
History
Director General’s Message
Policies
- Gender equality
- Environmental Sustainability
State Parties/Signatories

Leadership
Senior Management
Our Partners

Overview
Discover
Develop
Deliver
Build Capacity

Disease Areas
- Cholera
- Typhoid
- Dengue
- MERS
- Schistosomiasis
- Chikungunya
- COVID-19
- Other

Where We Work

Overview map
IVI Member State Relations

Journal Publications
International Vaccinology Course
News and stories
Annual Reports & Financial Statement

Korea Support Committee for IVI (KSC)

Copyright 2022 International Vaccine Institute. All Rights Reserved.

No translations available for this page

News and stories
Careers
Events
Contact us
Donate
한국어